HLA and Delayed Drug-Induced Hypersensitivity | Zendy

Bernardo SousaPinto | Zendy; Cláudia Correia | Zendy; Lídia Gomes | Zendy; Sara GilMata | Zendy; Luís Araújo | Zendy; Osvaldo Correia | Zendy; Luís Delgado | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HLA and Delayed Drug-Induced Hypersensitivity

Author(s) -

Bernardo SousaPinto,

Cláudia Correia,

Lídia Gomes,

Sara GilMata,

Luís Araújo,

Osvaldo Correia,

Luís Delgado

Publication year - 2016

Publication title -

international archives of allergy and immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.696

H-Index - 100

eISSN - 1423-0097

pISSN - 1018-2438

DOI - 10.1159/000448217

Subject(s) - abacavir , immunology , human leukocyte antigen , drug allergy , medicine , pharmacogenetics , allergy , immunogenetics , allele , pathogenesis , antigen , genotype , biology , genetics , gene , hepatitis b virus , virus , lamivudine

Delayed drug allergy reactions (DDAR) are potentially fatal. Certain human leukocyte antigen (HLA) alleles have been associated with delayed allergy reactions following the administration of particular drugs. Examples are HLA-B*57:01 (abacavir), HLA-B*15:02/HLA-A*31:01 (carbamazepine), and HLA-B*58:01 (allopurinol). Based on the identification of these associations, it may now be possible to prevent certain allergy reactions that were, until recently, considered unpredictable. In this review, we will focus on the pharmacogenetics of the best-studied associations between specific HLA alleles and delayed allergy reactions and describe the pathogenesis models proposed so far. Finally, we will evaluate the genetic screening strategies available and discuss the clinical relevance of a better understanding of the immunogenetics and mechanisms involved in DDAR.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research